Key statistics
As of last trade, Astria Therapeutics Inc (ATXS:NMQ) traded at 9.40, 113.15% above the 52 week low of 4.41 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.40 |
---|---|
High | 9.42 |
Low | 9.31 |
Bid | 9.30 |
Offer | 9.43 |
Previous close | 9.34 |
Average volume | 281.55k |
---|---|
Shares outstanding | 56.43m |
Free float | 49.67m |
P/E (TTM) | -- |
Market cap | 527.01m USD |
EPS (TTM) | -2.09 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:35 GMT.
More ▼
- Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
- Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
- Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
- European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
- Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
- Astria Therapeutics to Present at Upcoming Global Angioedema Forum
- Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
- Astria Therapeutics to Present at Upcoming Bradykinin Symposium
More ▼